發(fā)布時間：2019-07-04 17:20

【摘要】：背景: 臨床上對于腫瘤等惡性疾病的治療手段,已從傳統(tǒng)的手術、放療、化療擴展到了生物免疫治療。在這一領域中,細胞治療占主導地位。臍血以其豐富的干細胞、較弱的免疫細胞抗原性、簡單易行的采集和保存等多方面的優(yōu)勢,逐漸取代骨髓,而成為近年細胞治療中細胞的主要來源。因此臍血細胞的生物學性能、免疫學特性、殺傷腫瘤細胞(特別是血液系統(tǒng)腫瘤)的機制,成為了研究的熱點。 目的: 研究人臍血林巴細胞體外經(jīng)絲裂原刺激培養(yǎng)后的生物學、免疫學等方面的特性,并與健康人外周血淋巴細胞進行比較,為臍血淋巴細胞輸注治療在臨床上的應用提供客觀的指標和理論基礎。 材料和方法: Ficoll密度梯度離心法分離的人臍血及外周血單個核細胞,體外無血清體系培養(yǎng)5天,同時設加PHA(植物血凝素)和不加PHA兩組。觀察細胞克隆生長情況,并在培養(yǎng)前和培養(yǎng)后不同時間點收集細胞和培養(yǎng)上清。臺盼蘭染色法計算活細胞數(shù);流式細胞術檢測細胞的表型特征;ELIsA法檢測培養(yǎng)上清中IFN-γ含量;Trizol提取細胞的RNA,逆轉錄成cDNA后,用FRQ-PCR法進行IFN-γ及β-actin基因擴增,相對定量地比較細胞內(nèi)IFN-γ mRNA轉錄以情況。 結果: 1.MNC體外生長情況:PHA(+)組UCBMNC在培養(yǎng)過程中細胞花團的體積、數(shù)量、密集程度不斷增加;PBMNC細胞花團的生長情況遠不如UCBMNC旺盛。PHA(-)組UCBMNC在培養(yǎng)過程中未見明顯細胞花團,但細胞始終布滿培養(yǎng)孔;PBMNC無細胞花團,培養(yǎng)后期細胞分布甚至變得稀疏。 2.MNC細胞數(shù)量的擴增:PHA(+)組UCBMNC細胞擴增的最大值為
文內(nèi)圖片：
圖片說明：圖IUCBPHAG)組，，培養(yǎng)1天
[Abstract]:Background: the clinical treatment of malignant diseases such as tumor has been extended from traditional surgery, radiotherapy and chemotherapy to bioimmunotherapy. Cell therapy dominates in this field. Cord blood has gradually replaced bone marrow because of its rich stem cells, weak immune cell antigenicity, simple collection and preservation, and has become the main source of cells in cell therapy in recent years. Therefore, the biological performance and immunological characteristics of cord blood cells, and the mechanism of killing tumor cells (especially blood system tumors) have become the focus of research. Objective: to study the biological and immunological characteristics of human umbilical cord blood Limba cells stimulated by mitogen in vitro and to compare them with those of healthy peripheral blood lymphocytes, so as to provide an objective index and theoretical basis for the clinical application of cord blood lymphocytes infusion therapy. Materials and methods: human umbilical cord blood and peripheral blood mononuclear cells isolated by Ficoll density gradient centrifugation were cultured in serum-free system for 5 days. PHA (plant hemagglutinin) and no PHA were added at the same time. The cell clone growth was observed, and the cell and culture supernatant were collected at different time points before and after culture. The number of living cells was calculated by trypan blue staining, the phenotypic characteristics of the cells were detected by flow cytometry, the content of IFN- 緯 in the culture supernatant was detected by ELIsA assay, and the IFN- 緯 and 尾-actin genes were amplified by FRQ-PCR method after RNA, reverse transcription into cDNA, and the transcription of IFN- 緯 mRNA in the cells was compared relatively quantitatively. Results: the volume, number and density of UCBMNC cells in: PHA () group increased continuously during the culture process of 1.MNC in vitro, and the growth of PBMNC cells was much less exuberant than that of UCBMNC. PHA (-) group UCBMNC did not see obvious cell flower clusters during the culture process, but the cells were always covered with culture pores, and the cell distribution even became sparse in the later stage of culture. The maximum value of UCBMNC cell amplification in: PHA () group was as follows: the number of UCBMNC cells was amplified by the number of UCBMNC cells.
【學位授予單位】：南京醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2005
【分類號】：R329.2

【參考文獻】

相關期刊論文 前10條

1 周鳳麗,畢筱剛,張?zhí)焱?張扣興,唐英春;肺癌患者肺泡巨噬細胞細胞因子及其細胞殺傷活性的研究[J];癌癥;2001年09期

2 ;臍血輸注治療再生障礙性貧血的臨床及實驗研究[J];中國輸血雜志;2001年S1期

3 ;非骨髓清除性、無關供者臍血移植/輸注治療重型再生障礙性貧血Ⅱ型[J];中國輸血雜志;2001年S1期

4 王麗峰,盧學春;GVL作用研究現(xiàn)狀[J];白血病.淋巴瘤;2002年01期

5 粟毅,吳亞梅;細胞因子聯(lián)合化療治療晚期非小細胞肺癌的療效觀察[J];重慶醫(yī)學;2002年04期

6 李慧娟,鄒典定,趙東赤,張渝侯,谷小華;激活臍血單個核細胞體外抗白血病細胞株活性研究[J];中國當代兒科雜志;2001年06期

7 張伶,李維,黃宗干;體外誘導臍血造血細胞定向分化的研究[J];第三軍醫(yī)大學學報;2003年06期

8 葉韻斌,陳強,陳明水,李潔羽,吳允昆;植物血凝素對殺瘤細胞刺激作用的研究[J];福建醫(yī)藥雜志;1998年01期

9 孫新,劉莎,趙U

本文編號：2510081